NASDAQ: VBIV - VBI Vaccines Inc.

六个月盈利: -95.37%
部门: Healthcare

促销时间表 VBI Vaccines Inc.


关于公司

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.

更多详情
In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Выручка 0.0022
EBITDA -0.0461
P/S 2.47
P/BV 0.0623
EV/EBITDA 0.5178
Цена ао 0.58
ISIN CA91822J1030
Число акций ао 0.01557 млрд
Сайт https://www.vbivaccines.com
Див.доход ао 0
Дивиденд ао 0.25
Валюта usd
IPO date 1995-08-18
Sector Health Care
Industry Biotechnology
Валюта отчета usd
每日价格变化: 0% (0.0282)
每周价格变化: 0% (0.0282)
每月价格变化: 0% (0.0282)
3个月内价格变化: -96.15% (0.7329)
六个月内的价格变化: -95.37% (0.609)
每年价格变化: -94.87% (0.55)
3年内价格变化: -99.05% (2.96)
5年内价格变化: -95.46% (0.6217)
年初以来价格变化: -95.91% (0.69)

低估

姓名 意义 年级
P/S 0.9865 9
P/BV 1.14 9
P/E 0 0
EV/EBITDA -0.7112 0
全部的: 6

效率

姓名 意义 年级
ROA, % -106.77 0
ROE, % -1233.37 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0.7 7
全部的: 1.16

责任

姓名 意义 年级
Debt/EBITDA -0.9947 10
全部的: 8.2

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 294.64 10
盈利能力 Ebitda, % 15.66 3
盈利能力 EPS, % -60.52 0
全部的: 4.6



导师 职称 支付 出生年份
Mr. Jeffery R. Baxter FCMA President, CEO & Director 908.06k 1961 (63 年)
Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D. Chief Medical Officer 544.52k 1955 (69 年)
Ms. Nell Beattie CFO, Head of Corporate Development & Director N/A 1988 (36 年)
Ms. Athena Kartsaklis Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer N/A 1965 (59 年)
Mr. Avi Mazaltov Global Head of Manufacturing & GM of SciVac N/A 1962 (62 年)
Mr. Misha Nossov Senior VP of Global Commercial Supply Strategy & Head of Europe N/A
Mr. John Robert Dillman Chief Commercial Officer N/A 1968 (56 年)
Dr. David Evander Anderson Ph.D. Chief Scientific Officer 1970 (54 年)
Ms. Nicole Anderson Director of Corporate Communications & Investor Relations
Mr. T. Adam Buckley B.Sc., MBA Senior Vice President of Business Development 1976 (48 年)

地址: United States, Cambridge. MA, 160 Second Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.vbivaccines.com